Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $20.00 price target on the stock, down previously from $29.00.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) had its price target lowered by analysts at HC Wainwright from $75.00 to $35.00. They now have a "buy" rating on the stock.
MindMed to Participate at May Investor Conferences
New Studies Presented at the International Society for Health Economics and Outcomes Research Meeting (ISPOR 24) Show Growing Burden and Impact of Generalized Anxiety Disorder (GAD) in the US
MindMed Reports First Quarter 2024 Financial Results and Business Updates